164 related articles for article (PubMed ID: 38684511)
1. Patient-derived organoids of pancreatic ductal adenocarcinoma for subtype determination and clinical outcome prediction.
Matsumoto K; Fujimori N; Ichihara K; Takeno A; Murakami M; Ohno A; Kakehashi S; Teramatsu K; Ueda K; Nakata K; Sugahara O; Yamamoto T; Matsumoto A; Nakayama KI; Oda Y; Nakamura M; Ogawa Y
J Gastroenterol; 2024 Apr; ():. PubMed ID: 38684511
[TBL] [Abstract][Full Text] [Related]
2. Organoid Sensitivity Correlates with Therapeutic Response in Patients with Pancreatic Cancer.
Grossman JE; Muthuswamy L; Huang L; Akshinthala D; Perea S; Gonzalez RS; Tsai LL; Cohen J; Bockorny B; Bullock AJ; Schlechter B; Peters MLB; Conahan C; Narasimhan S; Lim C; Davis RB; Besaw R; Sawhney MS; Pleskow D; Berzin TM; Smith M; Kent TS; Callery M; Muthuswamy SK; Hidalgo M
Clin Cancer Res; 2022 Feb; 28(4):708-718. PubMed ID: 34789479
[TBL] [Abstract][Full Text] [Related]
3. Precision Medicine in Pancreatic Cancer: Patient-Derived Organoid Pharmacotyping Is a Predictive Biomarker of Clinical Treatment Response.
Seppälä TT; Zimmerman JW; Suri R; Zlomke H; Ivey GD; Szabolcs A; Shubert CR; Cameron JL; Burns WR; Lafaro KJ; He J; Wolfgang CL; Zou YS; Zheng L; Tuveson DA; Eshlemann JR; Ryan DP; Kimmelman AC; Hong TS; Ting DT; Jaffee EM; Burkhart RA
Clin Cancer Res; 2022 Aug; 28(15):3296-3307. PubMed ID: 35363262
[TBL] [Abstract][Full Text] [Related]
4. Subtype-Discordant Pancreatic Ductal Adenocarcinoma Tumors Show Intermediate Clinical and Molecular Characteristics.
Topham JT; Karasinska JM; Lee MKC; Csizmok V; Williamson LM; Jang GH; Denroche RE; Tsang ES; Kalloger SE; Wong HL; O'Kane GM; Moore RA; Mungall AJ; Notta F; Loree JM; Wilson JM; Bathe O; Tang PA; Goodwin R; Knox JJ; Gallinger S; Laskin J; Marra MA; Jones SJM; Renouf DJ; Schaeffer DF
Clin Cancer Res; 2021 Jan; 27(1):150-157. PubMed ID: 33051307
[TBL] [Abstract][Full Text] [Related]
5. Subtypes in pancreatic ductal adenocarcinoma based on niche factor dependency show distinct drug treatment responses.
Shinkawa T; Ohuchida K; Mochida Y; Sakihama K; Iwamoto C; Abe T; Ideno N; Mizuuchi Y; Shindo K; Ikenaga N; Moriyama T; Nakata K; Oda Y; Nakamura M
J Exp Clin Cancer Res; 2022 Mar; 41(1):89. PubMed ID: 35272688
[TBL] [Abstract][Full Text] [Related]
6. Morphological classification of pancreatic ductal adenocarcinoma that predicts molecular subtypes and correlates with clinical outcome.
N Kalimuthu S; Wilson GW; Grant RC; Seto M; O'Kane G; Vajpeyi R; Notta F; Gallinger S; Chetty R
Gut; 2020 Feb; 69(2):317-328. PubMed ID: 31201285
[TBL] [Abstract][Full Text] [Related]
7. Basal-like and classical cells coexist in pancreatic cancer revealed by single-cell analysis on biopsy-derived pancreatic cancer organoids from the classical subtype.
Juiz N; Elkaoutari A; Bigonnet M; Gayet O; Roques J; Nicolle R; Iovanna J; Dusetti N
FASEB J; 2020 Sep; 34(9):12214-12228. PubMed ID: 32686876
[TBL] [Abstract][Full Text] [Related]
8. Genetic assessment of pathogenic germline alterations in lysosomal genes among Asian patients with pancreatic ductal adenocarcinoma.
Koh Y; Kim H; Joo SY; Song S; Choi YH; Kim HR; Moon B; Byun J; Hong J; Shin DY; Park S; Lee KH; Lee KT; Lee JK; Park D; Lee SH; Jang JY; Lee H; Kim JA; Yoon SS; Park JK
J Transl Med; 2023 Oct; 21(1):730. PubMed ID: 37848935
[TBL] [Abstract][Full Text] [Related]
9. Patient-derived pancreatic tumour organoids identify therapeutic responses to oncolytic adenoviruses.
Raimondi G; Mato-Berciano A; Pascual-Sabater S; Rovira-Rigau M; Cuatrecasas M; Fondevila C; Sánchez-Cabús S; Begthel H; Boj SF; Clevers H; Fillat C
EBioMedicine; 2020 Jun; 56():102786. PubMed ID: 32460166
[TBL] [Abstract][Full Text] [Related]
10. Development of a Single-Cell Technique to Increase Yield and Use of Gastrointestinal Cancer Organoids for Personalized Medicine Application.
Gao M; Harper MM; Lin M; Qasem SA; Patel RA; Mardini SH; Gabr MM; Cavnar MJ; Pandalai PK; Kim J
J Am Coll Surg; 2021 Apr; 232(4):504-514. PubMed ID: 33253861
[TBL] [Abstract][Full Text] [Related]
11. Irbesartan overcomes gemcitabine resistance in pancreatic cancer by suppressing stemness and iron metabolism via inhibition of the Hippo/YAP1/c-Jun axis.
Zhou T; Xie Y; Hou X; Bai W; Li X; Liu Z; Man Q; Sun J; Fu D; Yan J; Zhang Z; Wang Y; Wang H; Jiang W; Gao S; Zhao T; Chang A; Wang X; Sun H; Zhang X; Yang S; Huang C; Hao J; Liu J
J Exp Clin Cancer Res; 2023 May; 42(1):111. PubMed ID: 37143164
[TBL] [Abstract][Full Text] [Related]
12. Implementing patient derived organoids in functional precision medicine for patients with advanced colorectal cancer.
Cartry J; Bedja S; Boilève A; Mathieu JRR; Gontran E; Annereau M; Job B; Mouawia A; Mathias P; De Baère T; Italiano A; Besse B; Sourrouille I; Gelli M; Bani MA; Dartigues P; Hollebecque A; Smolenschi C; Ducreux M; Malka D; Jaulin F
J Exp Clin Cancer Res; 2023 Oct; 42(1):281. PubMed ID: 37880806
[TBL] [Abstract][Full Text] [Related]
13. Pancreatic cancer-derived organoids - a disease modeling tool to predict drug response.
Frappart PO; Walter K; Gout J; Beutel AK; Morawe M; Arnold F; Breunig M; Barth TF; Marienfeld R; Schulte L; Ettrich T; Hackert T; Svinarenko M; Rösler R; Wiese S; Wiese H; Perkhofer L; Müller M; Lechel A; Sainz B; Hermann PC; Seufferlein T; Kleger A
United European Gastroenterol J; 2020 Jun; 8(5):594-606. PubMed ID: 32213029
[TBL] [Abstract][Full Text] [Related]
14. Standardized Methods Using EUS-guided Fine-needle Biopsy and a Minimal Medium Creates Three Pancreatic Cancer Organoids.
Ishida Y; Tsunoda T; Hamada Y; Tsuchiya N; Koga T; Kitaguchi T; Matsumoto K; Matsumoto S; Sasaki T; Nakashima R; Ishii F; Kajiwara M; Shirasawa S; Hasegawa S; Hirai F
Anticancer Res; 2022 Aug; 42(8):4103-4109. PubMed ID: 35896269
[TBL] [Abstract][Full Text] [Related]
15. Detecting drug resistance in pancreatic cancer organoids guides optimized chemotherapy treatment.
Hennig A; Baenke F; Klimova A; Drukewitz S; Jahnke B; Brückmann S; Secci R; Winter C; Schmäche T; Seidlitz T; Bereuter JP; Polster H; Eckhardt L; Schneider SA; Brückner S; Schmelz R; Babatz J; Kahlert C; Distler M; Hampe J; Reichert M; Zeißig S; Folprecht G; Weitz J; Aust D; Welsch T; Stange DE
J Pathol; 2022 Aug; 257(5):607-619. PubMed ID: 35373359
[TBL] [Abstract][Full Text] [Related]
16. Metabolic Profiling of Early and Late Recurrent Pancreatic Ductal Adenocarcinoma Using Patient-Derived Organoid Cultures.
Braun LM; Lagies S; Klar RFU; Hussung S; Fritsch RM; Kammerer B; Wittel UA
Cancers (Basel); 2020 Jun; 12(6):. PubMed ID: 32492856
[TBL] [Abstract][Full Text] [Related]
17. Development of Patient-Derived Gastric Cancer Organoids from Endoscopic Biopsies and Surgical Tissues.
Gao M; Lin M; Rao M; Thompson H; Hirai K; Choi M; Georgakis GV; Sasson AR; Bucobo JC; Tzimas D; D'Souza LS; Buscaglia JM; Davis J; Shroyer KR; Li J; Powers S; Kim J
Ann Surg Oncol; 2018 Sep; 25(9):2767-2775. PubMed ID: 30003451
[TBL] [Abstract][Full Text] [Related]
18. Comparison of endoscopic ultrasound-guided fine-needle aspiration and fine-needle biopsy to generate pancreatic cancer organoids: Randomized trial.
Wiessner JR; Orben F; Schäfer A; Fricke L; Schneider G; Reichert M; Herner A; Mayr U; Phillip V; Treiber M; von Figura G; Abdelhafez M; Schmid RM; Schlag C
Endosc Int Open; 2024 Mar; 12(3):E361-E366. PubMed ID: 38464982
[No Abstract] [Full Text] [Related]
19. CFTR Expression Analysis for Subtyping of Human Pancreatic Cancer Organoids.
Hennig A; Wolf L; Jahnke B; Polster H; Seidlitz T; Werner K; Aust DE; Hampe J; Distler M; Weitz J; Stange DE; Welsch T
Stem Cells Int; 2019; 2019():1024614. PubMed ID: 31191661
[TBL] [Abstract][Full Text] [Related]
20. Gene expression profiling of 1200 pancreatic ductal adenocarcinoma reveals novel subtypes.
Zhao L; Zhao H; Yan H
BMC Cancer; 2018 May; 18(1):603. PubMed ID: 29843660
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
